publication . Article . 2001

β-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise

Ellis, S. G.; Brener, S. J.; Lincoff, A. M.; Moliterno, D. J.; Whitlow, P. L.; Schneider, J. P.; Eric Topol;
  • Published: 27 Nov 2001
Background β-blocker (BB) use reduces infarct size in spontaneously occurring nonreperfused infarcts but probably does not change infarct size in patients treated with reperfusion therapy. A recent observational study suggested that BB use concurrent with percutaneous coronary intervention (PCI) decreased the risk of creatine kinase (CK)-MB elevation. The cogency of such a conclusion is dependent on the ability to risk-adjust for the multiple differences in patients treated with and without BBs. Methods and Results Using propensity score and multivariate regression analyses, 6200 consecutive patients were analyzed to assess the relationship between BB use before...
Medical Subject Headings: cardiovascular diseases
free text keywords: Physiology (medical), Cardiology and Cardiovascular Medicine, Percutaneous coronary intervention, medicine.medical_treatment, medicine, Cardiology, medicine.medical_specialty, Conventional PCI, Creatine kinase, biology.protein, biology, business.industry, business, Infarction, medicine.disease, Unstable angina, Interquartile range, Internal medicine, Angioplasty, Reperfusion therapy
Related Organizations
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue